Evidence map›Paper›PMID 42336675›Full record

ArticleClinical genetics2026

Neurodevelopmental Phenotypes and Brain Anomalies in Individuals With Heterozygous SEMA6A Variants.

Evan Burchfiel, Xiaonan Zhao, Nichole M Owen, Tia Gordon, Mahshid S Azamian, Eric C Kao, Fan Xia, Xi Luo, Jill A Rosenfeld, Seema R Lalani and 18 more

Abstract read
In one paragraph

Article in Clinical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Evan BurchfielDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Xiaonan ZhaoDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Nichole M OwenDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Tia GordonDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Mahshid S AzamianDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Eric C KaoDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Fan XiaDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Xi LuoDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Jill A RosenfeldDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Seema R LalaniDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Allison P OrtegaDepartment of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.
Steven B BleylDepartment of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.
Florence PetitClinical Genetics Department, Univ. Lille, CHU Lille, Lille, France.
Sulekha RajagopolanDepartment of Clinical Genetics, Liverpool Hospital, Liverpool, New South Wales, Australia.
Bénédicte DemeerCentre Hospitalier Universitaire de Amiens-Picardie, Amiens, France.
Meredith K GillespieDepartment of Genetics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Lijia HuangDepartment of Genetics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Matthew OsmondChildren's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.ORCID https://orcid.org/0000-0002-5886-873X
Kym M BoycottDepartment of Genetics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.ORCID https://orcid.org/0000-0003-4186-8052
Kyra E StuurmanDepartment of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Marjon A van SlegtenhorstDepartment of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Haley SollerDivision of Genetics and Genomic Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Céline JostUniversité Bourgogne Europe, CHU Dijon Bourgogne, Inserm, CTM UMR1231, Dijon, France.
Aurore GardeUniversité Bourgogne Europe, CHU Dijon Bourgogne, Inserm, CTM UMR1231, Dijon, France.
Hana SafraouLaboratoire de Génomique Médicale, Inserm, UMR1231, équipe GAD, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France.
Laurence FaivreUniversité Bourgogne Europe, CHU Dijon Bourgogne, Inserm, CTM UMR1231, Dijon, France.ORCID https://orcid.org/0000-0001-9770-444X
Victor FaundesLaboratorio de Genética y Enfermedades Metabólicas, Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile, Santiago, Chile.
Daryl A ScottDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-1460-5169

Funding

Wellcome TrustWellcome Trust WT223718/Z/21/Z
6 · The paper itself

Abstract

SEMA6A is a transmembrane protein that plays a role in axon guidance and cell migration. Sema6a null mice have cerebral anatomical defects and altered social interactions and working memory. However, the phenotypes associated with loss of SEMA6A function have not been clearly defined in humans. Here we describe 11 individuals who are heterozygous for putatively damaging variants affecting SEMA6A. All of these individuals (100%) had neurodevelopmental phenotypes that included developmental delay, intellectual disability, and/or autism spectrum disorder. Abnormal behaviors were seen in 73% with oppositional defiant disorder being diagnosed in 27% and acting out, overeating, and tantrums each being described in 18% of individuals. Disorders of attention were documented in 45%. Among the six individuals who had a brain MRI, 50% had at least one abnormal finding. Of the eight SEMA6A variants with known inheritance, five were inherited. Taken together, our data suggest that loss of SEMA6A function may be associated with an increased risk of neurodevelopmental phenotypes, abnormal behaviors, disorders of attention, and brain anomalies. Additional studies will be needed to determine if SEMA6A haploinsufficiency is best characterized as an autosomal dominant disorder with incomplete penetrance or as a risk factor for these phenotypes.

Indexed as

BrainGenetic Predisposition to DiseaseNeurodevelopmental DisordersSemaphorinsAdolescentAnimalsAutism Spectrum DisorderChildChild, PreschoolDevelopmental DisabilitiesFemaleGenetic Association StudiesHeterozygoteHumansIntellectual DisabilityMagnetic Resonance ImagingSEMA6A protein, humanSemaphorinsattention deficit disorderautism spectrum disorderCNS anomaliesdevelopmental delayneurodevelopmental disorderSEMA6A

Identifiers

PMID42336675
PMCPMC13432063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.